Merck & Co., Inc. (NYSE: MRK) Stock Competitors & Peer Comparison
See MRK's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MRK and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MRK | $150.33 | -1.32% | 371.3B | 46.83 | $3.21 | +2.24% |
| LLY | $1,148.20 | -0.98% | 1.1T | 36.48 | $31.49 | +0.59% |
| JNJ | $275.23 | +0.01% | 671.1B | 25.95 | $10.73 | +1.92% |
| ABBV | $256.34 | -1.49% | 453B | 25.16 | $10.19 | +2.67% |
| NVS | $159.99 | -1.90% | 304.1B | 18.41 | $8.69 | +2.97% |
| AZN | $162.70 | -1.26% | 252.3B | 17.57 | $9.26 | +2.00% |
| AMGN | $437.23 | -1.55% | 236B | 19.55 | $22.37 | +2.28% |
| NVO | $46.60 | -1.92% | 207B | 11.60 | $4.02 | +3.87% |
| GILD | $151.00 | -0.15% | 187.5B | -387.17 | -$0.39 | +2.14% |
| PFE | $28.45 | -1.25% | 162.1B | 9.33 | $3.05 | +6.04% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
MRK vs LLY Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while LLY trades at $1,148.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas LLY's P/E ratio is 36.48. In terms of profitability, MRK's ROE is +0.07%, compared to LLY's ROE of +0.93%. Regarding short-term risk, MRK is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for MRK.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
MRK vs JNJ Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, JNJ has a market cap of 671.1B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while JNJ trades at $275.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas JNJ's P/E ratio is 25.95. In terms of profitability, MRK's ROE is +0.07%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, MRK is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for MRK.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
MRK vs ABBV Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, ABBV has a market cap of 453B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while ABBV trades at $256.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas ABBV's P/E ratio is 25.16. In terms of profitability, MRK's ROE is +0.07%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, MRK is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for MRK.Check ABBV's competition here
Novartis AG (NYSE: NVS)
MRK vs NVS Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, NVS has a market cap of 304.1B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while NVS trades at $159.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas NVS's P/E ratio is 18.41. In terms of profitability, MRK's ROE is +0.07%, compared to NVS's ROE of +0.30%. Regarding short-term risk, MRK is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for MRK.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
MRK vs AZN Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, AZN has a market cap of 252.3B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while AZN trades at $162.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas AZN's P/E ratio is 17.57. In terms of profitability, MRK's ROE is +0.07%, compared to AZN's ROE of +0.22%. Regarding short-term risk, MRK is less volatile compared to AZN. This indicates lower risk in terms of short-term price fluctuations for MRK.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
MRK vs AMGN Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, AMGN has a market cap of 236B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while AMGN trades at $437.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas AMGN's P/E ratio is 19.55. In terms of profitability, MRK's ROE is +0.07%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, MRK is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for MRK.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
MRK vs NVO Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, NVO has a market cap of 207B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while NVO trades at $46.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas NVO's P/E ratio is 11.60. In terms of profitability, MRK's ROE is +0.07%, compared to NVO's ROE of +0.59%. Regarding short-term risk, MRK is less volatile compared to NVO. This indicates lower risk in terms of short-term price fluctuations for MRK.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
MRK vs GILD Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, GILD has a market cap of 187.5B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while GILD trades at $151.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas GILD's P/E ratio is -387.17. In terms of profitability, MRK's ROE is +0.07%, compared to GILD's ROE of -0.16%. Regarding short-term risk, MRK is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for MRK.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
MRK vs PFE Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, PFE has a market cap of 162.1B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while PFE trades at $28.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas PFE's P/E ratio is 9.33. In terms of profitability, MRK's ROE is +0.07%, compared to PFE's ROE of +0.05%. Regarding short-term risk, MRK is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for MRK.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
MRK vs BMY Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, BMY has a market cap of 136.5B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while BMY trades at $66.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas BMY's P/E ratio is 11.27. In terms of profitability, MRK's ROE is +0.07%, compared to BMY's ROE of +0.47%. Regarding short-term risk, MRK is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for MRK.Check BMY's competition here
Sanofi (NASDAQ: SNY)
MRK vs SNY Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, SNY has a market cap of 106.2B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while SNY trades at $44.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas SNY's P/E ratio is 9.64. In terms of profitability, MRK's ROE is +0.07%, compared to SNY's ROE of +0.06%. Regarding short-term risk, MRK is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for MRK.Check SNY's competition here
GSK plc (NYSE: GSK)
MRK vs GSK Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, GSK has a market cap of 100B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while GSK trades at $49.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas GSK's P/E ratio is 10.78. In terms of profitability, MRK's ROE is +0.07%, compared to GSK's ROE of +0.24%. Regarding short-term risk, MRK is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for MRK.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
MRK vs BIIB Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, BIIB has a market cap of 32.6B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while BIIB trades at $220.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas BIIB's P/E ratio is 13.94. In terms of profitability, MRK's ROE is +0.07%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, MRK is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for MRK.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
MRK vs HZNP Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas HZNP's P/E ratio is 61.86. In terms of profitability, MRK's ROE is +0.07%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, MRK is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for MRK.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
MRK vs GRFS Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, GRFS has a market cap of 6.6B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while GRFS trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas GRFS's P/E ratio is 8.96. In terms of profitability, MRK's ROE is +0.07%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, MRK is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for MRK.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
MRK vs OGN Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while OGN trades at $13.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas OGN's P/E ratio is 4.11. In terms of profitability, MRK's ROE is +0.07%, compared to OGN's ROE of +0.23%. Regarding short-term risk, MRK is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for MRK.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
MRK vs AMRN Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, AMRN has a market cap of 281.9M. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while AMRN trades at $13.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas AMRN's P/E ratio is -136.30. In terms of profitability, MRK's ROE is +0.07%, compared to AMRN's ROE of -0.06%. Regarding short-term risk, MRK is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for MRK.Check AMRN's competition here
Scilex Holding Company (NASDAQ: SCLX)
MRK vs SCLX Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, SCLX has a market cap of 46M. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while SCLX trades at $5.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas SCLX's P/E ratio is -0.14. In terms of profitability, MRK's ROE is +0.07%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, MRK is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for MRK.Check SCLX's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
MRK vs MIRA Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, MIRA has a market cap of 32.1M. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while MIRA trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas MIRA's P/E ratio is -0.53. In terms of profitability, MRK's ROE is +0.07%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, MRK is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for MRK.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLXW)
MRK vs SCLXW Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, SCLXW has a market cap of 32M. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while SCLXW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas SCLXW's P/E ratio is N/A. In terms of profitability, MRK's ROE is +0.07%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, MRK is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for MRK.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
MRK vs BDSIW Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, MRK's ROE is +0.07%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, MRK is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for MRK.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
MRK vs CRXT Comparison September 2026
Merck & Co., Inc. (NYSE: MRK) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRK stands at 371.3B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, MRK is priced at $150.33 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRK currently has a P/E ratio of 46.83, whereas CRXT's P/E ratio is -0.02. In terms of profitability, MRK's ROE is +0.07%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, MRK is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for MRK.Check CRXT's competition here